News and Trends 20 Feb 2019
Inflammatory Disease Treatment Backed by €20M Series A
The Swiss company Calypso Biotech has raised a sizeable €20M to fund its immunotherapy for an allergy-related inflammatory disease. The Series A round will help to develop Calypso’s antibody treatment for eosinophilic esophagitis, a condition where patients have an inflamed esophagus and difficulty swallowing. This condition is often linked with allergies to food, such as […]